Monomeric self-associating fusion polypeptides and therapeutic uses thereof

• US 7,666,622 B2
• Filed: 10/18/2006
• Issued: 02/23/2010
• Est. Priority Date: 10/19/2005
• Status: Active Grant

• Current Assignee: Regeneron Pharmaceuticals Incorporated
• Original Assignee: Regeneron Pharmaceuticals Incorporated
• Inventors: Karow, Margaret, Sharma, Prerna
• Primary Examiner(s): STANFIELD, CHERIE MICHELLE
• Application Number:
  US11/582,929
• Publication Number:
  US 20070087411A1
• Time in Patent Office: 1,224 Days
• Field of Search: None
• US Class Current: 435/69.1
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

Monomeric fusion polypeptides comprising R1-M-L-M, wherein R1 is a target ligand-binding domain, M is a multimerizing component, and L is a linker capable of allowing one M component to interact with the other M component to form a self-associating monomer, optionally comprising a second target ligand-binding domain R2. Preferred target ligands include interleukin (IL)-13, IL-1, insulin-like growth factor (IGF)-1 and IGF-2.

Claims

1. A nucleic acid encoding monomeric fusion polypeptide R1-M-L-M, wherein R1 is a ligand-binding domain of an interleukin receptor capable of binding an interleukin target ligand, M is a self-associating component, and L is a linker, wherein the nucleic acid encodes a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:

16.

3. A vector comprising the nucleic acid of claim 1.

4. A host-vector system for the production of a fusion polypeptide comprising the vector of claim 3 in a suitable host cell.

5. The host vector system of claim 4, wherein the cell is a E. coil, B. subtilis, BHK, COS or CHO cell.

6. A method of producing a fusion polypeptide, comprising growing the cells of the host-vector system of claim 4 under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

2. A nucleic acid encoding monomeric fusion polypeptide R1-M-L-M, wherein R1 is a first ligand-binding domain of an interleukin receptor capable of binding an interleukin target ligand, M is a self-associating component, L is a linker, and further comprising R2, wherein R2 is a second ligand-binding domain of an interleukin receptor which is capable of binding an interleukin target ligand that is the same or different from the interleukin target ligand of R1, wherein the nucleic acid encodes a fusion polypeptide comprising the amino acid sequence of SEQ ID NO:

10 or SEQ ID NO;

11.

9. A vector comprising the nucleic acid molecule of claim 2.

10. A host-vector system for the production of a fusion polypeptide comprising the vector of claim 9 in a suitable host cell.

11. The host vector system of claim 10, wherein the cell is a E. coil, B. subtilis, BHK, GOS or CHO cell.

12. A method of producing a fusion polypeptide, comprising growing the cells of the host-vector system of claim 10 under conditions permitting production of the fusion polypeptide and recovering the fusion polypeptide so produced.

7. A monomeric fusion polypeptide R1-M-L-M, wherein R1 is a ligand-binding domain of an interleukin receptor capable of binding an interleukin target ligand, M is a self-associating component, and L is a linker, comprising the amino acid sequence of SEQ ID NO:

16.

8. A monomeric fusion polypeptide R1-M-L-M further comprising R2, wherein R1 is a first ligand-binding domain of an interleukin receptor capable of binding an interleukin target ligand, R2 is a second ligand-binding domain of an interleukin receptor capable of binding an interleukin target ligand, M is a self-associating component, and L is a linker, comprising the amino acid sequence of SEQ ID NO:

10 or SEQ ID NO;

11.